Lineage Cell Therapeutics (LCTX) Gross Profit Growth (1y) (2012 - 2026)
Lineage Cell Therapeutics (LCTX) Gross Profit Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 41.37% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.76% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 16.94% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 68.41% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 254.83 Mn | 192.11 Mn | 1.73 Mn | 17.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.67% |
| Dec 31, 2025 | 141.05% |
| Sep 30, 2025 | -1.74% |
| Jun 30, 2025 | 99.85% |
| Mar 31, 2025 | 8.92% |
| Dec 31, 2024 | 48.14% |
| Sep 30, 2024 | 247.35% |
| Jun 30, 2024 | -55.97% |
| Mar 31, 2024 | -40.63% |
| Dec 31, 2023 | 1.05% |
| Sep 30, 2023 | -61.02% |
| Jun 30, 2023 | -28.58% |
| Mar 31, 2023 | -55.21% |
| Dec 31, 2022 | 88.07% |
| Sep 30, 2022 | 115.02% |
| Jun 30, 2022 | 1,020.93% |
| Mar 31, 2022 | 1,713.98% |
| Dec 31, 2021 | 300.00% |
| Sep 30, 2021 | 173.99% |
| Jun 30, 2021 | 24.44% |